Expression Levels and Significance of Gal-1 in Peripheral Blood and Placental Tissues of Pregnant Women with Fetal Growth Restriction Authors: Jinqiu Feng, Xiaomei Luan, Jinming Zhu Published: 2026 ABSTRACT AbstractObjectiveTo study the expression levels and significance of Gal-1 in the peripheral blood and placental tissues of pregnant women with fetal growth restriction (FGR).MethodsSixty samples were collected, including 30 early-onset FGR patients and 30 late-onset FGR patients from Xuzhou Maternity and Child Health Hospital. Thirty normal delivery puerperas served as controls. Clinical information such as parity, age, and BMI was analyzed. Five milliliters of cubital vein blood was drawn for serum Gal-1 detection via ELISA. Placental and fetal membrane tissues (1.0cm×1.0cm×0.5cm) were collected post-delivery for Gal-1 mRNA measurement using RT-PCR and for protein expression analysis via immunohistochemistry.ResultsNo significant differences were observed in parity, age, or BMI among the three groups (P>0.05). The gestational age in the early-onset FGR group was significantly lower than both the late-onset FGR and control groups (P<0.05). Serum Gal-1 levels were significantly higher in both FGR groups compared to controls (control: 105.344±17.178; early-onset FGR: 129.112±19.956; late-onset FGR: 118.773±18.908; P<0.05), with early-onset FGR showing the highest levels. In placental tissues, Gal-1 mRNA levels were significantly decreased in FGR groups versus controls (P<0.05), while Gal-1 were increased in Immunohistochemistry analysis.ConclusionDecreased Gal-1 expression in placental tissues and elevated serum Gal-1 levels may be associated with the development of FGR, particularly in early-onset cases, highlighting the potential role of Gal-1 as a biomarker in this condition.Keywords: fetal growth restriction, Galectin-1, placental tissues Introduction Fetal growth restriction (FGR), also known as intrauterine growth restriction, is a common pregnancy complication characterized by a fetus failing to achieve its expected growth potential, typically defined as an estimated fetal weight or abdominal circumference below the 10th percentile for gestational age.1 It significantly increases the risks of premature birth, stillbirth, neonatal death, and is associated with both short-term and long-term health consequences, including cognitive impairment, cardiovascular diseases, and metabolic disorders.2–4 The etiology of FGR is multifactorial and not fully elucidated, with placental dysfunction being the predominant underlying cause.1 Maternal conditions such as chronic hypertension, kidney disease, and autoimmune disorders like systemic lupus erythematosus are recognized risk factors that can impair placental development and function, potentially leading to FGR.2 A key pathological mechanism in many FGR cases is maternal vascular malperfusion (MVM), which involves reduced placental blood flow due to factors such as fibrin deposition, infarction, and chronic inflammation.3,5 Normal fetal growth is critically dependent on adequate placental development, particularly the process of trophoblast invasion and remodeling of the maternal spiral arteries. This remodeling transforms these vessels into low-resistance, high-capacity conduits, ensuring sufficient blood flow to the placental villi for maternal-fetal exchange.4 When this process is defective, it results in high-resistance blood flow, impairing placental size, villous development, and nutrient transfer. This defective placentation is a shared pathological feature of FGR and early-onset preeclampsia (PE).5,6 These placental abnormalities are often reflected in alterations of circulating angiogenic factors, such as increased levels of the anti-angiogenic protein soluble fms-like tyrosine kinase-1 (sFlt-1) and decreased levels of pro-angiogenic factors like placental growth factor (PlGF) and vascular endothelial growth factor (VEGF).7–9 Among the various molecular regulators of placental function, galectins, a family of glycan-binding proteins, have emerged as important players. They are involved in key pregnancy processes including maternal-fetal immune tolerance, trophoblast invasion, spiral artery remodeling, and angiogenesis.10 Dysregulation of several galectins has been linked to pregnancy pathologies. Galectin-1 (Gal-1), encoded by the LGALS1 gene, is a homodimeric prototype galectin implicated in cell differentiation, angiogenesis, and immune regulation.11 Its role in pregnancy is underscored by studies showing that low levels of Gal-1 are associated with preeclampsia, and that blocking Gal-1 function can induce a PE-like syndrome in mice.11 Similarly, Jin et al reported decreased levels of Gal-1 in the serum and placentas of women with FGR.12 In vitro studies have further demonstrated that knockdown of Gal-1 impairs trophoblast migration, highlighting its functional importance in placental development.13 Clinically, FGR is categorized into early-onset (<32 weeks of gestation) and late-onset (≥32 weeks) forms. This distinction is crucial as the two phenotypes differ in their severity, associated Doppler ultrasound findings, clinical progression, underlying placental pathology, linkage to hypertensive disorders, and management strategies.3,14,15 While Jin et al12 established a link between low Gal-1 and FGR, significant knowledge gaps remain regarding the differential expression patterns and pathophysiological mechanisms of Gal-1 between early-onset and late-onset FGR subtypes. These two phenotypes exhibit distinct clinical characteristics, placental pathologies, and disease progression patterns, yet systematic comparisons of Gal-1 expression across these subtypes are currently lacking. Understanding these differential expression patterns is critical for elucidating subtype-specific pathophysiological mechanisms and developing targeted diagnostic and therapeutic strategies. Therefore, this study aims to address this knowledge gap by quantitatively evaluating and comparing Gal-1 expression levels in maternal serum and placental tissues across well-characterized cases of early-onset FGR, late-onset FGR, and normal pregnancies. We hypothesize that Gal-1 exhibits distinct expression patterns between early-onset and late-onset FGR subtypes, reflecting their divergent underlying pathophysiologies. Elucidating these subtype-specific expression patterns may provide novel insights into FGR pathogenesis and enhance the clinical utility of Gal-1 as a biomarker for FGR stratification and management. Materials and Methods Clinical Data Sixty pregnant women with FGR who met the diagnostic criteria of Hadlock formula16 were collected from the Obstetrics Department of the Affiliated Xuzhou Maternity and Child Health Hospital of Xuzhou Medical University. The patients were divided into early-onset FGR group (<32 weeks) and late-onset FGR group (≥32 weeks), with 30 patients in each group. Another 30 normal pregnant women with no any pregnancy complication were collected from the same institution as the control group. Inclusion criteria: ① Patients who met the diagnostic criteria for fetal growth restriction in the ninth edition of “Obstetrics and Gynecology”; ② Patients with singleton natural conception; ③ Patients and their families provided informed consent; ④ No smoking, alcohol, or other bad habits. Exclusion criteria: ① Patients with a history of diabetes or mental disorders; ② Patients with cardiovascular, liver, kidney, or other organ dysfunction, malignant tumors, or immune diseases; ③ Patients with assisted reproduction or multiple pregnancies; ④ Patients with malnutrition or pre-pregnancy BMI<18.5kg/m2; ⑤ Patients with single umbilical artery, velamentous or marginal cord insertion, umbilical cord torsion, or umbilical cord edema; ⑥ Patients with incomplete clinical data. All enrolled pregnant women were screened and excluded if they had acute infections, chronic inflammatory diseases, autoimmune disorders, or recent use of immunomodulatory medications. Placental tissues were consistently collected from the central region of the maternal side, avoiding areas with visible infarcts, calcifications, or hematomas, to ensure uniformity in sampling. The sample size was determined a priori using G*Power 3.1 software. Based on preliminary data and effect sizes (f=0.4) from a previous study by Jin et al,12 a sample size of 30 per group was calculated to achieve 80% power (β=0.2) with a two-sided α level of 0.05 for a one-way ANOVA test. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Xuzhou Maternal and Child Health Hospital Affiliated to Xuzhou Medical University(2023-LS08). Written informed consent was obtained from all individual participants included in the study. Indications for iatrogenic preterm delivery in the early-onset FGR group included: (1) absent or reversed end-diastolic flow in the umbilical artery Doppler; (2) abnormal ductus venosus Doppler (absent or reversed a-wave); (3) biophysical profile score ≤4/10; (4) maternal indication (eg., worsening hypertension, HELLP syndrome); or (5) cessation of fetal growth over 2 weeks with oligohydramnios. For the late-onset FGR group, delivery timing was determined by standard clinical protocols, with delivery recommended when estimated fetal weight <3rd percentile, umbilical artery pulsatility index >95th percentile with reduced growth velocity, or abnormal cerebroplacental ratio. Control group deliveries occurred at term (≥37 weeks) following spontaneous labor or elective induction for obstetric indications (eg., post-dates, maternal request). Methods Detection of Gal-1 Levels in Serum Five milliliters of fasting venous blood was drawn from each group of antepartum pregnant women before treatment, left to stand for about half an hour, centrifuged at 3000r/min for 10 minutes, and the supernatant was collected, labeled, and immediately stored in a −80°C freezer. The expression level of Gal-1 in the serum samples was detected by ELISA kit (ab260053, Abcam) using the FRT-6100 microplate analyzer to measure the OD values of each sample, the GAPDH (ab252636, Abcam) as reference and the corresponding sample concentration values were calculated based on the standard curve.12 Fasting venous blood (5 mL) was drawn from all participants during the admission process, prior to the onset of labor and any medical intervention (eg., induction, cesarean section), and within 24 hours preceding delivery, before the initiation of any specific medical treatment or surgical procedure. The expression level of Gal-1 in the serum samples was detected using a commercial Human Gal-1 ELISA Kit (ab260053, Abcam) according to the manufacturer’s instructions. Serum samples were diluted 1:5 using the sample diluent buffer provided in the kit to ensure the measured concentrations fell within the optimal range of the standard curve (0.36–20 ng/mL). The FRT-6100 microplate analyzer was used to measure the OD values, and the corresponding sample concentration values (in pg/mL) were calculated based on the standard curve, factoring in the dilution factor. Detection of Gal-1 Expression Levels in Placental Tissues After the placenta was delivered, a central area of about 5.0 cm in radius on the maternal side of the placenta was taken under sterile conditions, and the decidua basalis was removed. Two pieces of placental tissue of about 1.0cm×1.0cm×0.5cm were taken. One piece of placental tissue was washed three times with cold physiological saline and DEPC water, then placed in a sterile tube and immediately stored in liquid nitrogen for protein and RNA extraction. Total RNA was extracted using the Trizol method, and its concentration was measured and reverse transcribed into cDNA (reagents purchased from Wuhan Saiweier Biotechnology Co.Ltd). Real-time PCR was performed using the LightCycler48 System (Roche, Switzerland) (reagents purchased from Wuhan Saiweier Biotechnology Co., Ltd). The primer sequences for the target gene GAL-S1 were: forward:5′-GGAGCTTGTCATCAATGGAAATC-3′, reverse: 5′-TGATGACCCTTTTGGCTCCC-3′. The target gene was amplified for 40 cycles, with glyceraldehyde-3-phosphate dehydrogenase as the internal reference (forward: 5′-GGCTCTCCAGAACATCATCCC-3′, reverse: 5′- CACCACCTTCTTGATGTCATCATAT-3′) and the 2−ΔΔCt method, and the relative expression was calculated with three sample and technique repetitions.12 Immunohistochemical Detection of Gal-1 in Placental Tissues The other piece of placental tissue was fixed in 10% neutral formaldehyde for more than 24 hours, embedded in paraffin, and cut into 4μm thick sections for immunohistochemical experiments. The SP two-step method was used to detect Gal-1 in placental tissues. The primary antibody was rabbit anti-human monoclonal Gal-1 antibody (1:1000, Affinity Biosciences LTD), and the steps were strictly followed according to the kit instructions.15 The expression level of Gal-1 was determined based on the percentage of positive cells and the intensity of cell staining. Cells with obvious brown-yellow granules in the membrane or cytoplasm were considered positive, while cells with no staining or the same color as the background were considered negative. The percentage of positive cells: ≤5% was scored as 0, 6%~25% as 1, 26%~49% as 2, and ≥50% as 3. The staining intensity of positive cells: no staining was scored as 0, light brown as 1, brown as 2, and dark brown as 3. The product of the percentage score and the staining intensity score was used as the evaluation criterion: 0~1 was considered negative, and >1 was considered positive. In addition to the semi-quantitative scoring by pathologists, the staining intensity of Gal-1 was objectively quantified using ImageJ software (National Institutes of Health, USA) with the IHC Profiler plugin. Five random fields per sample at 400x magnification were analyzed to calculate a mean optical density for each sample. Observation Indicators (1) Comparison of the basic data of the three groups of pregnant women; (2) Comparison of the levels of Gal-1 in the serum of the three groups of pregnant women; (3) Comparison of the expression levels of Gal-1 in the placental tissues of the three groups of pregnant women; (4) Analysis of the correlation between the expression of Gal-1 in the serum and placental tissues of pregnant women; (5) Analysis of the predictive value of serum Gal-1 levels for FGR. Statistical Analysis SPSS27 was used for data analysis. Data conforming to a normal distribution were expressed as mean ± standard deviation (), while data not conforming to a normal distribution were expressed as median (interquartile range). Comparisons of means among multiple samples were performed using one-way ANOVA, and further pairwise comparisons were performed using the t-test. Non-normally distributed data were analyzed using the Kruskal–Wallis H non-parametric test. Count data were analyzed using the χ2-test and expressed as numbers or percentages, and P<0.05 was regarded as significant. Prior to conducting ANCOVA, we assessed the assumptions of linearity and homogeneity of regression slopes. First, scatter plots of serum Gal-1 versus gestational age were examined for each group to visually assess linearity. Second, we tested the interaction between group and gestational age (Group × GA interaction term) to evaluate the parallel slopes assumption. A non-significant interaction term (P > 0.05) would indicate that the relationship between Gal-1 and gestational age does not differ significantly across groups, supporting the use of ANCOVA. If the interaction term were significant, we would proceed with separate regression analyses for each group or consider alternative approaches such as multiple regression with interaction terms. Results Analysis of Differences in Baseline Characteristics We analyzed the sample basic information difference. There were no significant differences in parity, age, and BMI among the three groups (P>0.05). These key baseline features showed no significant differences among three groups, aiding in better control of potential confounding factors and improving the internal validity of the findings. The gestational age of the early-onset FGR group was significantly lower than that of the late-onset FGR group and the control group (P<0.05), while there was no significant difference in gestational age between the late-onset FGR group and the control group (P>0.05). The incidence of preeclampsia was 20.0% (6/30) in early-onset FGR group and 13.3% (4/30) in late-onset FGR group. No statistically significant difference was observed between the two groups (P>0.05). These results suggested that early FGR-onset was characterized by shorter gestation weeks, while there was no significant difference in gestation weeks between late FGR and control groups. See Table 1. Table 1Comparison of General Conditions of the Three Groups of Pregnant Women ()GroupCasesAge (years)BMI (kg/m2)Parity [M(P25,P75)]Gravidity [M(P25,P75)]Diagnosis of PreeclampsiaGestational Age at DeliveryControl Group3028.130±3.91929.263±2.224M (2.000,1.000)M (2.000,1.000)039.333±1.145*Early-onset FGR3027.803±3.57628.857±2.196M (2.000,1.500)M (1.000,1.000)6(20.0%)30.913±0.628Late-onset FGR3027.203±3.12329.523±1.821M (3.000,3.000)M (1.000,1.000)4(13.3%)39.560±0.993*P-value0.7860.5250.4760.4070.7310.000Note: Compared with the early-onset FGR group, *P<0.05. Comparison of General Conditions of the Three Groups of Pregnant Women () Note: Compared with the early-onset FGR group, *P<0.05. Gal-1 Significantly Increased in Early-Onset FGR in ELISA Analysis ELISA revealed the significant difference of Gal-1 in different groups. The Gal-1 level in the control group was 105.344±17.178, in the early-onset FGR group it was 129.112±19.956, and in the late-onset FGR group it was 118.773±18.908. Compared with the control group, the Gal-1 levels were significantly higher in both the early-onset FGR group (P<0.05) and the late-onset FGR group (P<0.05), with the early-onset FGR group showing a higher level than the late-onset FGR group (P<0.05). This indicates that the expression of Gal-1 increases in FGR, particularly more pronounced in early-onset FGR. See Table 2. After adjusting for gestational age using ANCOVA, the significant difference in serum Gal-1 levels among the three groups remained (P < 0.05). Post-hoc comparisons confirmed that both the early-onset and late-onset FGR groups had significantly higher Gal-1 levels than the control group (P < 0.05), and the early-onset FGR group remained significantly higher than the late-onset group (P < 0.05). Table 2Analysis of Serum Gal-1 Levels Using Analysis of Covariance (ANCOVA) with Gestational Age as a CovariateItemControl Group (n=30)Early-Onset FGR Group (n=30)Late-Onset FGR Group (n=30)FvaluePvalueGestational age (weeks, )39.33 ± 1.1530.91 ± 0.6339.56 ± 0.99--Serum Gal-1 (pg/mL, )105.34± 17.18129.11 ± 19.96118.77 ± 18.91--ANCOVAGroup effect (adjusted for GA)16.52< 0.001Covariate (Gestational age, GA)2.870.094Pairwise Comparisons (Difference in adjusted means, pg/mL)Early-onset FGR vs Control Group25.41---<0.001Late-onset FGR vs Control Group12.86---0.018Early-onset FGR vs Late-onset FGR12.55---0.022Notes: Data are presented as mean ± standard deviation (). The Pvalue for the group effect in the ANCOVA model is significant (P< 0.001), indicating that serum Gal-1 levels are significantly different among groups after adjusting for the effect of gestational age. Pairwise comparisons were conducted using the Tukey HSD test.Abbreviations: ANCOVA, Analysis of covariance; FGR, Fetal Growth Restriction; GA, Gestational Age. Analysis of Serum Gal-1 Levels Using Analysis of Covariance (ANCOVA) with Gestational Age as a Covariate Notes: Data are presented as mean ± standard deviation (). The Pvalue for the group effect in the ANCOVA model is significant (P< 0.001), indicating that serum Gal-1 levels are significantly different among groups after adjusting for the effect of gestational age. Pairwise comparisons were conducted using the Tukey HSD test. Abbreviations: ANCOVA, Analysis of covariance; FGR, Fetal Growth Restriction; GA, Gestational Age. Expression Levels of Gal-1 mRNA in the Placental Tissues of the Three Groups of Pregnant Women The expression levels of Gal-1 mRNA in placental tissues significantly differed among the three groups of pregnant women. In the Control Group, the average expression level was 3.477±2.715, which was significantly higher compared to both the early-onset FGR group (0.498±0.444, P < 0.05) and the late-onset FGR group (0.900±0.743, P < 0.05). The early-onset FGR group showed a markedly reduced expression level compared not only to the control group but also to the late-onset FGR group (P < 0.05), indicating distinct expression patterns of Gal-1 mRNA across different stages of FGR. These findings suggest that Gal-1 plays varying roles in the pathophysiology of early and late-onset FGR. See Table 3. Table 3Expression Levels of Gal-1 mRNA in the Placental Tissues of the Three Groups of Pregnant WomenGroupExpression Level of Gal-1 mRNA in Placental TissuesP-value (vs Control)P-value (Inter-Group)Control Group3.477±2.715--Early-onset FGR0.498±0.4446.3725E-8-Late-onset FGR0.900±0.7431.7185E-70.012Notes: Statistical significance was determined by one-way ANOVA followed by appropriate post-hoc tests. The overall P-value for differences among the three groups is <0.01.Abbreviations: FGR, Fetal Growth Restriction; SD, Standard Deviation. Expression Levels of Gal-1 mRNA in the Placental Tissues of the Three Groups of Pregnant Women Notes: Statistical significance was determined by one-way ANOVA followed by appropriate post-hoc tests. The overall P-value for differences among the three groups is <0.01. Abbreviations: FGR, Fetal Growth Restriction; SD, Standard Deviation. Expression Differences of Gal-1 in Placental Tissues in Different Groups Figure 1 shows the expression of Gal-1 in placental tissues observed through DAB staining (×400 magnification) in immunohistochemical analysis. The normal pregnancy control group (A) displays a lower level of Gal-1 expression [Score:0]; the early-onset FGR group (B) shows a significant increase in Gal-1 expression with notably darker staining [Score:3]; the late-onset FGR group (C) also exhibits increased Gal-1 expression, though to a lesser extent than the early-onset FGR group [Score:2]. This indicates that in FGR patients, particularly those with early-onset FGR, there is a significant increase in Gal-1 expression in placental tissues, suggesting that Gal-1 may have different mechanisms of action or serve as a potential biomarker in different types of FGR. See Figure 1. Representative immunohistochemical staining of Gal-1 in placental tissues (DAB staining). (A) Normal pregnancy control group. (B) Early-onset FGR group. (C) Late-onset FGR group. Consistent with the representative images and manual scoring, quantitative analysis using ImageJ confirmed a significantly higher optical density of Gal-1 staining in the early-onset FGR group compared to both the late-onset FGR and control groups. The late-onset FGR group also showed higher staining than the control group (P < 0.05).See Figure 1 and Supplementary Figure 1. Correlation Between Serum and Placental Tissue Gal-1 Expression A Spearman’s rank correlation analysis was performed to assess the relationship between serum Gal-1 levels and placental Gal-1 mRNA levels across all participants. A significant negative correlation was observed. No significant correlation was found between serum Gal-1 levels and semi-quantitative IHC scores. The assumption of homogeneity of regression slopes was tested and confirmed (Group×GA interaction: F=1.245, P=0.294), indicating that the relationship between serum Gal-1 and gestational age did not differ significantly across the three groups. Visual inspection of scatter plots supported the linearity assumption within the observed range of gestational ages (Figure 2). Scatter plot showing the negative correlation between serum Gal-1 levels and relative placental Gal-1 mRNA expression levels. Diagnostic Value of Serum Gal-1 for FGR To assess the potential of serum Gal-1 as a diagnostic biomarker for FGR, a ROC curve analysis was performed. When comparing all FGR patients (early and late-onset combined) against controls, the Area Under the Curve (AUC) was 0.81. See Figure 3. Receiver Operating Characteristic (ROC) curve analyzing the diagnostic performance of serum Gal-1 levels for distinguishing all FGR patients from healthy controls. Discussion FGR, a common obstetric complication, involves multiple factors such as maternal (advanced age, malnutrition), fetal (multiple pregnancies, congenital malformations), placental (structural abnormalities causing hypoperfusion), and pregnancy complications (antepartum hemorrhage). These can lead to placental dysfunction, impacting fetal growth by disrupting substance exchange. Placental hypoperfusion is a key mechanism, with management focusing on monitoring and timely delivery due to the lack of effective treatments, and clinical management often involves regular monitoring and timely termination of pregnancy. This difference helps to identify and distinguish different types of FGR and may inform clinical management and intervention. Some studies have shown that Gal-1 is widely present in various tissues and expressed in trophoblasts in the placenta,8 in endometrial stroma, fetal membranes, and decidua, affecting cell differentiation, mRNA splicing, and trophoblast invasion.14,15 Importantly, it is crucial role in promoting maternal-fetal immune tolerance, regulating the dilation of early placental decidual vessels16,17 and enhancing trophoblast invasion through Sda terminal glycosylation mechanism. The abnormal Gal-1 is closely related to pathological pregnancies, including FGR, preeclampsia, gestational diabetes, and chorioamnionitis. The establishment of maternal-fetal blood circulation is an important link in maintaining pregnancy, and this process depends on the formation of the vascular system during endometrial decidualization. The vascular response related to pregnancy is similar to the damage of blood supply by tumor cells to maintain their growth, mainly triggered by trophoblast-mediated signals. Gal-1 has multiple mechanisms of action in angiogenesis, including effects on endothelial cell proliferation, migration, and lumen formation. Freitag et al11 showed that Gal-1 exhibits pro-angiogenic functions in early pregnancy, promoting vasodilation through the vascular endothelial growth factor (VEGF) receptor 2 signaling pathway. In addition, Gal-1 may be involved in the mechanisms related to placental and maternal spiral artery remodeling, and through its mRNA-binding function, Gal-1 can regulate angiogenesis by binding to the mRNA of genes related to angiogenesis. This study showed that Gal-1 is mainly expressed in the syncytiotrophoblast and vascular endothelial cells of the placenta. Freitag et al11 also revealed that Gal-1 expression in endometrial stroma, fetal membranes, decidua, and trophoblasts, supporting this study’s findings. This widespread expression pattern suggests multiple roles for Gal-1 in placental development and function. In pregnancies affected by FGR, Gal-1 mRNA level in placental tissues are reduced, leading to decreased Gal-1 protein synthesis, potentially contributing to FGR pathology. Freitag et al11 demonstrated that Gal-1 enhances VEGF2 signaling, promoting angiogenesis and uterine spiral artery remodeling in pregnant mice. Gal-1 interacts with maternal spiral artery smooth muscle cells, promoting apoptosis and vascular wall remodeling. Reduced Gal-1 expression may therefore decrease placental angiogenesis, increase vascular permeability, and impair placental blood supply, affecting maternal-fetal substance exchange and trophoblast nutrient uptake, indirectly impacting fetal growth, and ultimately leading to FGR. Our results revealed that the Gal-1 levels were increased in the early-onset FGR and its may promote angiogenesis and remodeling of the spiral arteries of the uterus by enhancing the VEGF2 signaling pathway through the abnormal placental angiogenesis compensation mechanism. Meanwhile, upregulation of Gal-1 may also be involved in regulating the immune tolerance state at the maternal-fetal interface, helping to maintain an appropriate immune environment to support the development of early pregnancy. Our finding of elevated serum Gal-1 in FGR appears to contrast with the report by Jin et al,12 who observed decreased circulating Gal-1 in FGR patients compared to controls. Several methodological and clinical factors may account for this discrepancy. First, Jin et al did not stratify FGR by onset timing (early vs late), and their cohort may have been enriched with late-onset cases given the reported mean gestational age at delivery (approximately 36–37 weeks). Our data demonstrate that late-onset FGR exhibits a less pronounced elevation in serum Gal-1 compared to early-onset FGR, potentially approaching levels observed in uncomplicated pregnancies. However, the decrease in Gal-1 levels observed in late FGR may be associated with a decline in placental function, resulting in reduced angiogenesis, increased vascular permeability, and inadequate placental blood supply. In addition, the reduction of Gal-1 may lead to increased apoptosis of trophoblast cells, affecting their invasive ability and normal remodeling of the myometrium, thereby interfering with substance exchange and indirectly affecting fetal growth. This study showed that the expression level of Gal-1 in placental tissues is reduced, and the expression of serum Gal-1 is elevated, showing a negative correlation. The relationship between them may reflect the complex role of Gal-1 in the maternal-fetal interface and systemic immune regulation. The mechanism of how Gal-1 in placental tissues and serum interact is currently unclear. Possible mechanisms include the release of Gal-1 from placental tissues into the blood circulation, or the elevation of serum Gal-1 as a compensatory response to reduced placental function. Further studies with larger sample sizes are needed to clarify the negative correlation between them and its specific mechanism and significance. A central and complex finding of our study is the discordance between Gal-1 mRNA and protein expression in placental tissues. While RT-PCR indicated decreased mRNA levels in FGR groups, IHC revealed increased protein expression. This paradox invites critical examination. It is possible that post-transcriptional mechanisms, such as enhanced mRNA stability or translation efficiency, lead to a higher protein yield per mRNA molecule in the FGR placenta. Alternatively, the pathological environment might alter Gal-1 protein turnover, reduce its degradation and lead to accumulation. The semi-quantitative nature of IHC, despite our efforts to objectify it with manual scoring and ImageJ, remains a limitation. Therefore, while the increased staining is evident, the precise magnitude of the protein increase should be interpreted with caution. Future studies employing quantitative methods like Western Blotting are essential to confirm this observation. Future studies will focus on employing Western Blotting for precise protein quantification and utilizing in vitro trophoblast models to investigate the functional consequences of modulating Gal-1 expression on key processes like invasion, angiogenesis, and immune modulation. The discordance between decreased placental Gal-1 mRNA and increased protein/serum levels likely reflects complex post-transcriptional mechanisms. In FGR, reduced transcriptional activity may be offset by stress-induced enhancement of translation efficiency, impaired protein degradation, or altered cellular redistribution. Additionally, elevated serum Gal-1 may derive from maternal compensatory responses rather than direct placental release, supported by its negative correlation with placental mRNA. These findings underscore that Gal-1 regulation in FGR occurs at multiple levels—transcriptional, translational, and systemic—beyond simple gene expression changes. The elevated serum Gal-1 in FGR patients, even after adjusting for gestational age, highlighting the potential role of Gal-1 as a biomarker for FGR risk stratification and subtype identification. The ROC analysis yielded a promising but not definitive AUC of 0.81. For a biomarker to be clinically transformative, it must provide information beyond standard clinical parameters (eg., ultrasound biometry, Doppler velocimetry). Future large-scale, prospective studies are needed to determine if serum Gal-1 adds independent predictive value to existing diagnostic algorithms. In summary, this study not only confirms the aberrant expression of Gal-1 in FGR but further reveals its differential expression patterns between early-onset and late-onset FGR, suggesting that Gal-1 may be involved in distinct pathophysiological mechanisms underlying these two subtypes. The elevated serum Gal-1, particularly in early-onset FGR, may reflect a compensatory response to placental dysfunction, potentially via its roles in angiogenesis and immune regulation. Future studies integrating analyses of related signaling pathways (eg., VEGF, immune tolerance) are warranted to elucidate the precise mechanisms of Gal-1 in FGR pathogenesis. These findings position Gal-1 as a potential biomarker for stratifying FGR subtypes and informing targeted management strategies. This study has several limitations that should be considered when interpreting the results. First, the sample size, though justified by a power calculation, is moderate, and findings should be validated in a larger, multi-center cohort. Second, while we controlled for several key confounders, unmeasured variables could potentially influence Gal-1 expression. Fourth, the cross-sectional nature of this study captures associations but cannot establish causality. Finally, the absence of in vitro or in vivo functional data means that the proposed mechanisms by which Gal-1 influences FGR pathophysiology remain speculative and are an important avenue for future investigation. An additional limitation of our immunohistochemical analysis is the use of a single stain for Gal-1 without co-staining for specific cellular markers (eg., cytokeratin for trophoblasts). While the morphological context strongly suggests localization within syncytiotrophoblasts and vascular endothelium based on tissue architecture, future studies employing double-labeling immunofluorescence would be valuable to definitively confirm the specific cell types expressing Gal-1. Conclusion In summary, this study demonstrates differential Gal-1 expression patterns between early-onset and late-onset fetal growth restriction (FGR), with elevated serum Gal-1 and reduced placental mRNA levels. These findings suggest distinct subtype-specific pathophysiological mechanisms and highlight the potential of serum Gal-1 as an adjunctive biomarker for FGR risk stratification when combined with existing clinical parameters. However, we acknowledge that the lack of gestational age-matched controls and cross-sectional design limit our ability to distinguish disease-specific pathology from developmental timing effects. The clinical utility of serum Gal-1—whether for early identification of at-risk pregnancies prior to ultrasound diagnosis or for guiding management decisions—requires validation in prospective longitudinal studies. We therefore position Gal-1 as a complementary biomarker within a multimodal assessment framework, pending further investigation. Funding Statement There is no funding to report. Ethics Approval and Consent to Participate This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of Xuzhou Maternal and Child Health Hospital Affiliated to Xuzhou Medical University(2023-LS08). We obtained signed informed consent from the participants in this study. Disclosure All of the authors had no any personal, financial, commercial, or academic conflicts of interest separately. References